Generic Lenacapavir Wins FDA Tentative Approval, but U.S. Yeztugo Users Can’t Switch Yet
Article excerpt
The FDA has granted tentative approval to the first generic injectable lenacapavir for HIV prevention, made by India’s Dr. Reddy’s Laboratories, the company and its partners announced Monday, Nov. 2. Lenacapavir is the drug Gilead Sciences sells for prevention in the U.S. as Yeztugo, the twice-yearly PrEP shot. Dr. Reddy’s version will cost $40 per person per year in the 120 low- and middle-income countries covered by Gilead’s license, Unitaid said, a price “in line with oral PrEP.” It cannot be sold in the U.S. Yeztugo is still under patent, and its U.S. list price is $28,218 a year, The Associated Press reported. “For someone at risk of HIV, taking a pill every day to prevent a disease they don’t have is a hard thing to ask,” said Neil Buddy Shah, CEO of the Clinton Health Access Initiative. “Two injections a year, of a product that is almost 100% effective at preventing HIV, changes that entirely.” People don’t always take a daily pill, “and if you do not take it, you cannot get protected against HIV,” Carmen Pérez Casas, Unitaid’s HIV lead, told the AP. “With lenacapavir, we are much more hopeful.” A tentative approval “does not allow the applicant to market the generic drug product,” the FDA’s glossary says. Final approval waits until “all patent or exclusivity issues have been resolved.” (So no, your pharmacist can’t swap in a $40 version.) The partners’ release...
Keep reading with a free account
The rest of this article, and every signal for Gilead, is in your free account.
Extracted from this sentence
The shot made $305 million in the third quarter, and Johanna Mercier, Gilead’s chief commercial and corporate affairs officer, put its pharmacy-benefit coverage at “about 70% or so,” Gayety reported Oct. 30.
